2026-09-20T17:12:49Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/356792022-01-13T07:54:52Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
A. Gregory Sorensen and Teodro Forcht Dagi.
Wine, David
Sloan School of Management.
Harvard University--MIT Division of Health Sciences and Technology
Sloan School of Management
2007-01-10T17:01:23Z
2007-01-10T17:01:23Z
2006
2006
http://hdl.handle.net/1721.1/35679
76838462
Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology; and, (S.M.)--Massachusetts Institute of Technology, Sloan School of Management, 2006.
Includes bibliographical references (leaves 57-59).
I study several aspects of the value in performing oncology clinical trials using screening biomarkers to preferentially select and enroll responders. From trial reports and investigational reports on potential biomarkers, I construct a series of six cases comparing the trial as conducted to a hypothetical trial using different screening and eligibility criteria. These cases illustrate, within limits of the model, what difference the use of a plausible biomarker test may have on trial size, cost, number of patients screened, and number of patients exposed to experimental treatment without benefit.
by David Wine.
S.M.
58 leaves
2697725 bytes
2700104 bytes
application/pdf
application/pdf
eng
Massachusetts Institute of Technology
M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
http://dspace.mit.edu/handle/1721.1/7582
Harvard University--MIT Division of Health Sciences and Technology.
Sloan School of Management.
Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development
Thesis
application/pdf
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="adf2b60b-521d-4e2b-bc07-e5dc9bd13503">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2006</PublicationDate>
<Authors>
<Author>
<DisplayName>Wine, David</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Harvard University--MIT Division of Health Sciences and Technology.</Keyword>
<Keyword>Sloan School of Management.</Keyword>
<Abstract>I study several aspects of the value in performing oncology clinical trials using screening biomarkers to preferentially select and enroll responders. From trial reports and investigational reports on potential biomarkers, I construct a series of six cases comparing the trial as conducted to a hypothetical trial using different screening and eligibility criteria. These cases illustrate, within limits of the model, what difference the use of a plausible biomarker test may have on trial size, cost, number of patients screened, and number of patients exposed to experimental treatment without benefit.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>